newsfilter
← Latest News
GlobeNewswire·

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

  • OKYO Pharma Limited will participate in the Cantor Global Healthcare Conference held September 9-11, 2026, with a presentation scheduled for Thursday, September 10 at 8:35 AM ET.
  • Presenters for the session include Chief Medical Officer Flavio Mantelli, MD, PhD, & Chief Development Officer Gary Jacob, PhD, moderated by Eric Fitzgerald of Cantor Fitzgerald.
  • The company will offer one-on-one meetings during the conference following recent FDA Type D meeting validation for its regulatory & clinical path for urcosimod.
  • OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026 to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain (NCP) in approximately 111 patients.
  • The company recently filed its Annual Report reflecting a strengthened cash position.